The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | MRD in multiple myeloma: determining response
Rafael Fonseca
• 1 Jun 2018
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the importance of measurable residual disease (MRD). Dr Fonseca describes the results of a study that found that patients with multiple myeloma (MM) who were MRD-positive had a similar outcome regardless of the type of response observed.
